1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED : 31ST MARCH 2014.

  (Rupees in '000')
    Un -audited  Audited
S. No. Particulars Quarter ended Year Ended Year Ended
    31.03.2014 31.12.2013 31.03.2013 31.03.2014 31.03.2013
PART-I          
1 (a) Income from Operation        
    Gross Sales
18,213
19,323
17,481
77,960
76,818
    Less: Excise Duty
237
1,036
1,280
3,932
5,282
  Net Sales
17,976
18,287
16,201
74,028
71,536
  (b) Other Operating Income 
-
-
-
-
323
  Total Income from Operation
17,976
18,287
16,201
74,028
71,859
2 Expenditure
-
-
-
-
-
  (a) Consumption of Materials
409
5,884
3,152
18,048
21,402
  (b) Purchase of Goods Traded
6,651
3,503
1,144
13,275
5,460
  (c) (Increase)/Decrease in stock in trade
1,785
(1,467)
2,434
2,012
1,702
  (d) Staff Cost
5,758
6,730
5,566
25,313
25,748
  (e) Depreciation
656
656
659
2,624
2,619
  (f) Other Expenditure
2,587
3,047
2,556
11,923
12,083
  Total Expenditure
17,846
18,353
15,511
73,195
69,014
3 Profit/Loss from Operation Before Other Income (1-2)
130
-66
690
833
2,845
4 Other Income/(Loss)
287
636
266
1,273
775
5 Profit/Loss before Interest & Exceptional items (3+4)
417
570
956
2,106
3,620
6 Interest
(125)
270
467
841
2,021
7 Profit/Loss after Interest but before exceptional items (5-6)
542
300
489
1,265
1,599
8 Exceptional items 
-
-
-
-
-
9 Profit/Loss before Tax (7-8)
542
300
489
1,265
1599
10 Tax Expenses (Provision for Taxation):      Current tax
-
-
-
229
297
    Deffered tax
-
-
-
371
504
     
 
11 Net Profit/Loss after Tax (9-10)
542
300
489
665
798
12 Paid up Equity Share Capital (Face Value 10/- Per Share)
354,35
354,35
354,35
354,35
354,35
[Net of allotment money in arrears]
13 Reserves Excluding Revaluation Reserves 
-
-
-
9,093
8,428
14 Earning per share (EPS) before extraordinary item (not Annualised)
-
-
-
-
-
  Basic & Diluted
-
-
-
0.15
0.17
PART-II A. PARTICULARS  OF SHAREHOLDING 
 
1 Public Shareholding
 
  i) Number of Shares
28,94,901
28,94,901
29,04,901
28,94,901
29,04,901
  ii) Percentage of shareholding
63.33%
63.33%
63.55%
63.33%
63.55%
2 Promoters and promoter group Shareholding 
 
a) Pledged/Encumbered
 
i) Number of shares
-
-
-
-
-
  ii) Percentage of shares (as a % of the total shareholding of
-
-
-
-
-
  promoter and promoter group)
 
  iii) Percentage of shares (as a% of the total share capital of the company)
-
-
-
-
-
  b) Non-encumbered
 
i) Number of Shares
1,676,099
1,676,099
1,666,099
1,676,099
1,666,099
  ii) Percentage of shares (as a% of the total shareholding
36.67%
36.67%
36.45%
36.67%
36.45%
  of promoter and promoter group)
 
  iii) Percentage of shares (as a % of the total share capital of the company)
100%
100%
100%
100%
100%
 
  B. INVESTORS COMPLAINTS 3 Months ended 31.03.2014
  Pending at Begining of the Quarter  NIL
  Received During the Quarter NIL
  Disposed of During the Quarter NIL
  Remaining at the end of the Quarter NIL

 

STATEMENT OF ASSETS AND LIAB ILITIES (Rupees in '000')
Particulars As at 31.03.2014 As at 31.03.2013
(Audited) (Audited)
A   EQUITY AND LIABILITIES  
1   SHARE HOLDERS FUND  
  a)  Share Capital 35,435 35,435
  b)   Reserves and Surplus 27,814 27,149
  Sub-Total of Shareholders Fund 63,249 62,584
2   NON CURRENT LIABILITIES  
  a) Long term borrowing  18,809 22,554
  b) Deffered tax liability( net) 3,975 3,604
  c) Other  long term liability 168 147
  d) Long term Provision - -
  Sub-Total of Non Current Liabilities 22,952 26,305
3   CURRENT LIABILITIES  
  a) Short term borrowing  - -
  b) Trade payable 8,497 4,013
  c) Other current liabilities 5,221 5,652
  d) Short term provision - -
  Sub-Total of Current Liabilities 13,718 9,665
       
   
Total ( 1+2+3)
99,919 98,554
 
B   ASSETS  
1   NON CURRENT ASSETS  
  a) Fixed Assets 37,165 39,761
  b) Non current investments 3,159 3,159
  c) Long term loans and advances  13,343 13,543
  d) Other Non current assets 2,316 599
  Sub-Total of Non Current Assets 55,983 57,062
2   CURRENT ASSETS  
  a) Inventories 17,169 18,606
  b) Trade receivable 13,334 12,717
  c) Cash and cash equivalents 12,013 9,384
  d) Short term loans and advances 1,420 785
    Sub-Total of  Current Assets 43,936 41,492
       
   
Total ( 1+2 )
99,919 98,554

 

NOTES :-

  1. The above financial results have been taken on record at a meeting of Board of Directors held on 30-05-2014
  2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
  3. Previous period figures have been regrouped wherever required.

 

  For and on behalf of the Board
  M/s. COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
30.05.2014 Chairman & Managing Director.

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in